Mawson Infrastructure Group Inc. — Director's Dealing 2020

Dec 31, 2020

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Wize Pharma, Inc. (WIZP)
CIK: 0001218683
Period of Report: 2020-12-29

Reporting Person: Rubini Jonathan Brian (10% Owner)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2020-12-29	Common Stock	X	4074074	—	Acquired	6529813	Direct
2020-12-29	Common Stock	S	33951	—	Disposed	6495862	Direct
2020-12-29	Common Stock	X	350000	—	Acquired	6845862	Direct
2020-12-29	Common Stock	S	2692	—	Disposed	6843170	Direct
2020-12-29	Common Stock	X	259037	—	Acquired	7102207	Direct
2020-12-29	Common Stock	S	2159	—	Disposed	7100048	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2020-12-29	Warrant (right to buy)	$0.27	X	4074074	Disposed	2024-12-19	Common Stock (4074074)	Direct
2020-12-29	Warrant (right to buy)	$0.16	X	350000	Disposed	2023-10-23	Common Stock (350000)	Direct
2020-12-29	Warrant (right to buy)	$1.97	X	259037	Disposed	2020-12-31	Common Stock (259037)	Direct

Footnotes

F1: On December 23, 2020 the registrant has voluntary reduced the exercise price of warrants to $0.001. The reporting person exercised a warrant to purchase shares of the registrant's common stock for the reduced exercise price.

F2: On December 29, 2020 the reporting person exercised a warrant to purchase 4,074,074 shares of the registrant's common stock for $0.27 a share. The reporting person paid the exercise price on a cashless basis, resulting in the registrant withholding of 33,951 of the warrant shares to pay the exercise price and issuing to the reporting person the remaining 4,040,123 shares.

F3: On December 29, 2020 the reporting person exercised a warrant to purchase 350,000 shares of the registrant's common stock for $0.16 a share. The reporting person paid the exercise price on a cashless basis, resulting in the registrant withholding of 2,692 of the warrant shares to pay the exercise price and issuing to the reporting person the remaining 347,308 shares.

F4: On December 29, 2020 the reporting person exercised a warrant to purchase 259,037 shares of the registrant's common stock for $1.97 a share. The reporting person paid the exercise price on a cashless basis, resulting in the registrant withholding of 2,159 of the warrant shares to pay the exercise price and issuing to the reporting person the remaining 256,878 shares.

F5: Exercisable five days following the public announcement of positive clinical data results for LO2A.

F6: The expiration date was extended from 11/16/2029 to 12/31/2020.